Increased Intestinal Delivery of Viable Saccharomyces boulardii by Encapsulation in Microspheres
- 647 Downloads
Although probiotics are of a major potential therapeutic interest, their efficacy is usually limited by poor bioavailability of viable microorganisms on site. The aim of this study was to protect the probiotic Saccharomyces boulardii from degradation in order to ensure a greater number of viable yeast in the colon.
Alginate microspheres coated with or not with chitosan were used to encapsulate the yeast by an extrusion method. The efficiency of encapsulation was assessed both in vitro and in vivo.
In vitro, less than 1% of the non-encapsulated probiotic survived after 120 min at pH 1.1, whereas the majority of encapsulated yeast cells remained entrapped within both types of microspheres. Further exposure to a pH 6.8 allowed the release of about 35% of viable yeasts. In vivo, the percentage of viable yeast excreted over 96 h after a single oral dose of 2 × 108 cfu/100 g in rats was 2.5% for non-encapsulated yeast and reached 13.3 and 9.0% of the dose administered for the uncoated and chitosan-coated microspheres, respectively.
Given the dose-dependent efficacy of S. boulardii and the efficiency of microencapsulation in protecting the yeast from degradation, alginate microspheres could be of great interest in therapeutic applications of the yeast.
Keywordsalginate gastrointestinal transit microspheres probiotic Saccharomyces boulardii
This work was supported by Biocodex, France. The authors acknowledge Pr M. J. Butel and her team for free access to the Microbiology Laboratory, Université Paris Descartes, Dr G. Dumortier and Dr P. Boy for their contribution to the statistical analysis of the data, and Pr L. Cynober for his thoughtful comments and sound advice.
- 7.L. V. McFarland, C. M. Surawicz, R. N. Greenberg, R. Fekety, G. W. Elmer, K. A. Moyer, S. A. Melcher, K. E. Bowen, J. L. Cox, Z. Noorani, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA. 271:1913–1918 (1994).PubMedCrossRefGoogle Scholar
- 9.C. M. Surawicz, L. V. McFarland, R. N. Greenberg, M. Rubin, R. Fekety, M. E. Mulligan, R. J. Garcia, S. Brandmarker, K. Bowen, D. Borjal, and G. W. Elmer. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis. 31:1012–1017 (2000).PubMedCrossRefGoogle Scholar
- 32.A. Ainsley Reid, J. C. Vuillemard, M. Britten, Y. Arcand, E. Farnworth, and C. P. Champagne. Microentrapment of probiotic bacteria in a Ca(2+)-induced whey protein gel and effects on their viability in a dynamic gastro-intestinal model. J Microencapsul. 22:603–619 (2005).PubMedCrossRefGoogle Scholar